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Available online 26 September 2016Human skin ﬁbroblasts were isolated from a 40-year-old hereditary spastic paraplegia patient carrying an
intronic splice site mutation (c.1687 + 2 T N A) in SPAST, leading to hereditary spastic paraplegia type 4
(SPG4). Fibroblasts were reprogrammed using episomal plasmids carrying hOCT4, hSOX2, hKLF4, hL-MYC and
hLIN28. The generated transgene-free line iPS-SPG4-splice retained the speciﬁc mutation with no additional ge-
nomic aberrations, expressed pluripotency markers and was able to differentiate into cells of all germ layers in
vitro. The generated iPS-SPG4-splice line might be a useful platform to study the pathomechanism of SPG4.
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Hereditary spastic paraplegia (HSP) is a neurodegenerative disorder
characterised by lower limb spasticity and weakness due to axonal de-
generation in the corticospinal tract. The most common form of HSP is
the autosomal dominantly inherited spastic paraplegia type 4 (SPG4)
which is caused by mutations within the SPAST gene encoding for the
microtubule-severing enzyme spastin (Schule et al., 2016). To study
the underlying disease mechanisms, the iPSC line iPS-SPG4-splice was
generated by delivery of episomal plasmids encoding human OCT4,
SOX2, KLF4, L-MYC and LIN28 in skin ﬁbroblasts from a 40-year-old pa-
tient with a phenotype of pure HSP (Okita et al., 2011). Gait difﬁculties
developed early in childhood with a slowly progressive course of dis-
ease. The quality of the generated iPSCs was investigated by genotypic
and functional assays. Genomic integrity was analysed by comparative
SNP analysis of ﬁbroblasts and the generated iPSCs (Fig. 1A),
resequencing of themutation-site (Fig. 1B) and exclusion of genomic in-
tegration of episomal plasmids (Fig. 1C). The expression of pluripotency
markers on protein and RNA level was assessed by alkaline phosphatase
staining (ALP) (Fig. 2A), immunocytochemical stainings of OCT4, TRA-(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Genomic characterisation of generated iPS-SPG4-splice. (A) SNP array analysis of ﬁbroblast (F-SPG4-splice) and generated iPSCs (iPS-SPG4-splice) reveal genomic integrity. Data is
shown in whole genome view (WGV) and expressed as the weighted log2 ratio of the copy number on the left Y-axis (blue line), and the chromosome number on the X-axis. (B) Sanger
sequencing of the region containing the heterozygous splice site mutation c.1687 + 2 T N A in F-SPG4-splice and iPS-SPG4-splice. (C) RT-PCR veriﬁcation of the absence of plasmid
integration in iPS-SPG4-splice. Plasmid-speciﬁc primer for hOCT3/4, SOX2, KLF4, and L-MYC with DNA from iPS-SPG4-splice, plasmid samples as positive control, and ddH2O as
negative control were used.
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NANOG, KLF4, c-MYC, SOX2, REX1, DNMT3B and TDGF1 in comparison
to human embryonic stem cell lines (HuES-H6 / HuES\\H9) and ﬁbro-
blasts (Fig. 2C). Additionally, the potential of generated iPSCs to differ-
entiate into cells of all three germ layers was investigated. iPSCs were
able to differentiate into neurons expressing β-III-tubulin, muscle cells
positive for α-smooth muscle actin (SMA), and early endodermal cells
positive for α-fetoprotein (AFP) (Fig. 2D).
2. Materials and methods
2.1. Reprogramming of ﬁbroblast to iPSCs
Patient ﬁbroblasts carrying a heterozygous splice site mutation
(c.1687 + 2 T N A) in SPAST were derived from skin biopsies bydissection and cultivation in ﬁbroblast medium consisting of Dulbecco's
modiﬁed eagle's medium (DMEM) high glucose (Life technologies)
with 10% fetal bovine serum (FBS, Life technologies). After approx.
10 days of cultivation at 37 °C and 5% CO2 ﬁbroblasts were collected
and expanded by medium change every 2–3 days. Reprogramming
was achieved by nucleofection of 1 × 105 cells with 1 μg of each plasmid
(hOCT4, hSOX2, hKLF4, hL-MYC and hLIN28 (Okita et al., 2011)) using the
Nucleofector 2D system (Lonza). After reprogramming, cells were re-
placed in onewell of a 6-well plate and cultivated for 1 day in ﬁbroblast
medium. After a period of 2 days in ﬁbroblast medium supplemented
with 2 ng/ml FGF-2 (Peprotech) cells were transferred to Essential 8
(E8) medium containing 100 μM NaB (Sigma-Aldrich). 3–4 weeks
after reprogramming, iPSC colonies were picked manually and further
cultivated on Matrigel-coated 6-well dishes using E8 medium. IPSCs
were split in a ratio of 1:6–1:12 by adding PBS/EDTA (0.02% EDTA in
Fig. 2. Functional characterisation of generated iPS-SPG4-splice by (A) alkaline phosphatase (ALP) activity and the expression of speciﬁc pluripotency marker identiﬁed via (B)
immunocytochemical staining of OCT4 (green), TRA1–81 (red) as well as NANOG (green) and SSEA-4 (red). Nuclei are counterstained with DAPI (blue). Scale bar = 50 μm. (C) qRT-
PCR with cDNA from iPS-SPG4-splice, HuES\\H6, HuES-H9 and ﬁbroblasts and pluripotency speciﬁc primers OCT4, NANOG, KLF4, C-MYC, SOX2, REX1, DNMT3B and TDGF1 normalized
to the housekeeping gene GAPDH and the hESCs HuES\\H6. (D) Immunostainings of ectodermal (β-III-tubulin (TUJ), scale bar = 100 μm), endodermal (α-fetoprotein (AFP), scale
bar = 50 μm) and mesodermal (α-smooth-muscle-actin (SMA), scale bar =50 μm) markers reveal the differentiation potential of iPS-SPG4-splice. Nuclei are counterstained with
DAPI (blue).
Table 2
Primers used for validation of pluripotency genes.
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mediumwith 40%KOSR (Life technologies), 10%DMSO (Sigma-Aldrich)
and 1 μM Y-27632 (Abcam Biochemicals).
2.2. SNP array analysis
DNA was isolated using the DNeasy blood & tissue kit (Qiagen) ac-
cording to themanufacturer's guidelines. Using theAffymetrix CytoScan
HD technology (Affymetrix) SNP array analysis was performed by using
2 μg of DNA of the iPSC line as well as the original ﬁbroblast line. Raw
data was processed using Affymetrix Chromsome Analysis Suite
(ChAS) 2.0 software.Table 1
Primers (Okita et al., 2011) used for integration analysis by PCR.
Forward sequence Reverse sequence
KLF4 CCACCTCGCCTTACACATGAAG TAGCGTAAAAGGAGCAACATAG
L-MYC GGCTGAGAAGAGGATGGCTAC TTTGTTTGACAGGAGCGACAAT
OCT3/4 CATTCAAACTGAGGTAAGGG TAGCGTAAAAGGAGCAACATAG
SOX2 TTCACATGTCCCAGCACTACCAG TTTGTTTGACAGGAGCGACAAT2.3. Sequencing of mutation site
Using the3130xl Genetic Analyzer (Applied Biosystems) and a prim-
er set ﬂanking the mutation (c.1687 + 2 T N A) in SPAST, the mutation
site was analysed by applying standard procedures and visualization
with Staden 2.0.0b10 software (Staden Sourceforge).Forward sequence Reverse sequence
c-MYC ATTCTCTGCTCTCCTCGACG CTGTGAGGAGGTTTGCTGTG
DNMT3 ACGACACAGAGGACACACAT AAGCCCTTGATCTTTCCCCA
GAPDH AGGTCGGAGTCAACGGATTT ATCTCGCTCCTGGAAGATGG
KLF4 CCATCTTTCTCCACGTTCGC CGTTGAACTCCTCGGTCTCT
NANOG CAAAGGCAAACAACCCACTT TGCGTCACACCATTGCTATT
OCT4 GGAAGGTATTCAGCCAAACG CTCCAGGTTGCCTCTCACTC
REX1 AACGGGCAAAGACAAGACAC AACTCACCCCTTATGACGCA
SOX2 TGATGGAGACGGAGCTGAAG GCTTGCTGATCTCCGAGTTG
TDGF1 GGTCTGTGCCCCATGACA AGTTCTGGAGTCCTGGAAGC
Table 3
Antibodies used for validation of pluripotency genes and in vitro differentiation potential.
Antibody Dilution Manufacturer
Pluripotency rabbit anti-NANOG 1:50 Stemgent
goat anti-OCT4 1:100 Santa-Cruz
mouse anti-SSEA4 1:500 Abcam
mouse anti-TRA-1-80 1:500 Merck-Millipore
In vitro differentiation mouse anti-AFP 1:200 Sigma-Aldrich
mouse anti-SMA 1:100 Dako
mouse anti-TUJ 1:1000 Sigma-Aldrich
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DNA was isolated as described before. Using plasmid speciﬁc
primers (see Table 1) as well as the three episomal plasmids (pCXLE-
hUL, pCXLE-hSK and pCXLE-hOCT4) as positive control the integration
was analysed. Therefore, RT-PCR reactions were performed using
GoTaq G2 DNA Polymerase (Promega) according to the manufacturer's
instruction. PCR products were separated on a 2.0% agarose gel and vi-
sualized with Midori Green.
2.5. Alkaline phosphatase staining
For ALP staining iPSCswere cultivated on 12-well plates and ﬁxed in
4% paraformaldehyde (PFA) for 1 minute. After 3 times washing in PBS
staining solution (40 μl Naphthol AS-MX phosphate alkaline solution
(Sigma-Aldrich) and 1 ml Fast Red (1 mg/ml, Sigma Aldrich)) was
added for 30 min. ALP-positive colonies were stained dark red.
2.6. Immunocytochemical staining
iPSCs were cultivated on 24-well plates on coverslips until
conﬂuency of 60–80%. After ﬁxation in 4% paraformaldehyde (PFA) for
15 min cells were washed 3 times with PBS and incubated in blocking
buffer (PBS, 1% FCS, 0.1% Triton X-100) for 45 min. Cells were stained
for 1 h at room temperature (RT) with the primary antibody (see
Table 3). After 3washes in PBS, cells were incubatedwith the secondary
antibody (Alexa488 or Alexa568 diluted 1:300 (Life technologies)) in
the dark at RT for 1 h. Nuclear counterstainingwas achieved by addition
of DAPI (1:10,000) for 15min at RT in the dark. After embedding in Pro-
LongDiamondAntifadeMountant cells were analysedwith Axio Imager
Z1 with ApoTome (Zeiss).2.7. qRT-PCR of pluripotency marker
RNA was isolated using the High Pure RNA Isolation Kit (Roche) ac-
cording to the manufacturer's guidelines. Reverse transcription was
performed using the Transcriptor High Fidelity cDNA Synthesis Kit
(Roche). Using Light Cycler 480 SYBR Green I Master (Roche) and spe-
ciﬁc pluripotency gene primers (see Table 2) qRT-PCR was performed.
Runs were performed as triplicates and CT-values were normalized
using the 2-ΔΔCt method with the hESC line HuES-H6 as reference and
GAPDH as housekeeping gene.
2.8. In vitro differentiation potential
For embryonic body (EB) generation iPSCswere cultivated in EBme-
dium consisting of 80% DMEM/F12 (Life technologies), 20% KOSR, 1×
NEAA, 1× Pen/Strep, 2 mM L-Glutamine and 0.1 mM 2-
Mercaptoethanol on AggreWell 800 plates (Stemcell Technologies)
with medium change at day 2. EBs were collected on day 4 and plated
on 0.1% gelatine (Sigma-Aldrich) coated coverslips. Cells were cultivat-
ed for additional 2–3 weeks with medium change every other day and
analysed by immunocytochemical staining using antibodies against
AFP (α-fetoprotein), SMA (α-smoothmuscle actin) and TUJ (β-III-tubu-
lin) (see Table 3).
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